Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...
Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...
Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and ...
Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...
The price you pay for Rezdiffra may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...
The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a ...
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...
Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...
Zacks.com on MSN2d
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpMadrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...
Reports Q4 revenue $103.3M, consensus $97.81M. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Looking back on 2024, I’m incredibly ...
BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on ...
Madrigal Pharmaceuticals Inc (MDGL) reports robust financial performance with significant milestones in Rezdiffra's launch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback